About ACRX

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. The company's late-stage pipeline includes ARX-04 (sufentanil sublingual tablet, 30 mcg) for the treatment of moderate-to-severe acute pain in a medically supervised setting; and Zalviso (sufentanil sublingual tablet system) for the management of moderate-to-severe acute pain in adult patients in the hospital setting.
Primary Exchange: NASDAQ
SIC Measuring & Controlling Devices, NEC
NAICS Surgical and Medical Instrument Manufacturing

ACRX is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 247.9 M 2.47865E+08 234 234 0.01% 0.000149537 78 K 78286
UBIO Proshares UltraPro Nasdaq Biotechnology 31.1 M 3.10775E+07 228 228 0.01% 8.62846E-05 9 K 8780
IBB iShares Nasdaq Biotechnology Index Fund 8.2 B 8.24908E+09 222 222 0.03% 0.0003 2.8 M 2794840
ITOT iShares Core S&P Total U.S. Stock Market ETF 18.7 B 1.87292E+10 3,568 3568 0.0% 0 223 K 222591
IWC iShares Microcap ETF 916.2 M 9.16246E+08 1,452 1452 0.05% 0.0005 503 K 502931

Wait, Before You Leave...